ÐÂÔÂÖ±²¥appÏÂÔØ

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information

Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment

11 - 12 June 2015, San Francisco, United States


Introduction
Course Description:

Raw material requirements in a cGMP environment are often overlooked as a company develops new products. Depending on the product being developed, e.g., tablets and capsules vs. biotechnology products, as few as fifteen to twenty or as many as sixty raw materials need to be sourced before the process can be moved from initiation through completion.

This highly interactive two day seminar on raw material requirements in a cGMP environment will:

Consider Health Canada, FDA, USP and EP requirements.
Examine a variety of the issues surrounding raw materials to include what materials should be tested and to what extent during Phase 1, 2, 3 and commercial production.
Cover testing requirements during each phase and what may be optional (regulatory risk) until the product moves to its next phase.
Determine what options exist - even within a Phase 2 or Phase 3 testing framework.
Discuss compendial vs. non-compendial testing and how to respond when no method is available.
Discuss how a 90 percent vs. a 90.0 percent minimum purity analysis can delay initiation of testing.
Explore the number of lots required for testing before reduced testing might occur and why some companies don't accept this route.
Review the use of individual samples vs. composite samples for testing.
Explore ASQ testing to include how to choose attributes and sample size.
The objective of this two day seminar is to explore raw materials and their requirements – issues and solutions. It will also explore how water impacts the final product since water is the single largest raw material that is used within most processes. Another objective is to assure that your organization is maintaining itself within a cGMP compliance framework. Case studies to include Warning Letters will be discussed to illustrate regulatory raw material issues.

Learning Objectives:

Upon completing this course on raw material requirements in a cGMP environment participants will:

Understand how various types of raw materials may impact the user.
Learn of the impact of raw materials in the timely production of a product.
Determine the single most used raw material in large molecule production and what it means to the user.
Find the sources of analyses assistance for raw materials.
Appreciate the requirements for Phase 1 through commercial manufacturing.
Initiation of additional testing -- when?
Examination of regulatory risk (ICH Q9).
Why use compendial testing in lieu non-compendial testing.
Testing requirements -- when is enough?
The impact of ASQ on sample size and attribute testing.


Note: Use coupon code 232082 and get 10% off on registration.
Speakers
  • Barry A. Friedman, Ph.D Consultant in Biotechnology, Regulatory Compliance and Aseptic Processing Arena
    Barry A. Friedman, PhD, is a Consultant in the Biotechnology, Regulatory Compliance and Aseptic Processing Arena. Dr. Friedman possesses over 30 years of industrial managerial experience in various aspects of biopharmaceuticals and medical devices to include regulatory compliance, expert witness testimony, GLP/GMP, quality control, auditing, sterility assurance, microbiological/analytical validations and fermentation technology.

    Prior to becoming an independent consultant, Dr. Friedman was associated with Cambrex Bio ÐÂÔÂÖ±²¥appÏÂÔØs, a contract manufacturer of GMP bulk biopharmaceuticals located in Baltimore, Maryland. As the Director of Quality Control, he managed a multi-shift Department of thirty one individuals involved in client management, the receipt and testing of raw materials, environmental monitoring and microbiology, analytical chemistry and QC compliance for the production of Phase 1, 2, 3 and commercial products manufactured from bacteria, yeast and mammalian cells. In this capacity, Dr Friedman enjoyed many client and regulatory interactions, both domestic and international.

    Prior to 2000, Dr. Friedman was the Laboratory Director for Chesapeake Biological Laboratories, a contract Aseptic Fill n’ Finish manufacturer located in Baltimore, Maryland. In addition to the professional history listed above, other associations have included W.R. Grace, Sigma Chemical Co., Sherwood Medical, Becton Dickinson, American Cyanamid and Union Carbide.

    Dr. Friedman received his B.S. degree in Microbiology from Ohio State University, his M.S. from Michigan State University in Microbial Genetics, and his PhD from Ohio State University in Microbiology., United States

Venue
TBD

TBD, San Francisco, San Francisco, 94101, United States

Useful links

Organised by
ComplianceOnline
Contact information
Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*